Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,803 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06085664 | A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy | recruiting | Phase 1 / Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06276491 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | recruiting | Phase 1 | 282 | Xencor, Inc.INDUSTRY | 4 | Aug 25, 2026 | clinicaltrials |
| NCT07316686 | Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma | recruiting | Phase 1 | 18 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02068794 | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer | active not recruiting | Phase 1 / Phase 2 | 34 | Mayo ClinicOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03184753 | Genetically Modified T Cells Against Ovarian Cancer | terminated | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03356795 | Intervention of CAR-T Against Cervical Cancer | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03362606 | Engineered Immune Effectors Against Ovarian Cancer | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03362619 | Engineered Immune Effectors Against Cervical Cancer | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04019327 | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | terminated | Phase 1 / Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07783282 | A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer | not yet recruiting | Phase 1 | 56 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Aug 24, 2026 | clinicaltrials |
| NCT04221542 | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 479 | AmgenINDUSTRY | 10 | Aug 21, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT05805371 | PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 21 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06774963 | A Phase 1 Study of LNCB74 in Advanced Solid Tumors(LNCB74-01) | recruiting | Phase 1 | 145 | NextCure, Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT07778498 | A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. | not yet recruiting | Phase 1 / Phase 2 | 150 | Phrontline BiopharmaINDUSTRY | 0 | Aug 21, 2026 | clinicaltrials |
| NCT00977457 | Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery | active not recruiting | Phase 1 | 1,045 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04457232 | Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation(FAPI PET Prost) | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04673448 | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 18 | University of WashingtonOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05636111 | Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06785636 | A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC(P300) | recruiting | Phase 1 / Phase 2 | 120 | Pathos AI, Inc.INDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03604315 | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF | recruiting | Phase 1 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT04506567 | Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC | active not recruiting | Phase 1 | 60 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications(POTENTIATE) | terminated | Phase 1 | 85 | Boundless Bio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07772882 | Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer | not yet recruiting | Phase 1 | 24 | Rebecca ArendOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03096054 | A Phase I Trial of LY3143921 Hydrate in Solid Tumours | completed | Phase 1 | 69 | Cancer Research UKOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04432597 | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | completed | Phase 1 / Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06966024 | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | recruiting | Phase 1 | 60 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07182149 | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | recruiting | Phase 1 | 150 | Normunity AccelCo, Inc.INDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07470853 | A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | recruiting | Phase 1 | 265 | Whitehawk Therapeutics, Inc.INDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04840589 | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors | suspended | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT05225363 | Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer | recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06792552 | A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 738 | NextCure, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07665515 | Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(OVACT) | recruiting | Phase 1 | 50 | Epitopea LtdINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06826768 | A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC | recruiting | Phase 1 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07765940 | Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer(COPRA424) | not yet recruiting | Phase 1 / Phase 2 | 52 | RadAlliance Therapeutics, IncINDUSTRY | 0 | Aug 14, 2026 | clinicaltrials |
| NCT02217956 | Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma(CHIPASTIN) | completed | Phase 1 | 30 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02515877 | Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers(HPV-RX) | completed | Phase 1 | 15 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02830724 | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | recruiting | Phase 1 / Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05519449 | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | recruiting | Phase 1 | 272 | Janux TherapeuticsINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 97 | NextCure, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06040970 | Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer | recruiting | Phase 1 / Phase 2 | 54 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06399757 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Apollo Therapeutics LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07042802 | A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 180 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 25, 2026source: clinicaltrials